| 前收市價 | 132.88 |
| 開市 | 136.80 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 133.82 - 138.29 |
| 52 週波幅 | 74.70 - 140.32 |
| 成交量 | |
| 平均成交量 | 28,858 |
| 市值 | 617.51B |
| Beta 值 (5 年，每月) | 0.19 |
| 市盈率 (最近 12 個月) | 47.30 |
| 每股盈利 (最近 12 個月) | 2.90 |
| 業績公佈日 | 2024年8月07日 |
| 遠期股息及收益率 | 1.86 (1.40%) |
| 除息日 | 2024年3月22日 |
| 1 年預測目標價 | 無 |
ZacksThe Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Qualcomm, Caterpillar, CSP and Epsilon Energy
Novo Nordisk, Qualcomm, Caterpillar, CSP and Epsilon Energy are included in this Analyst Blog.
ZacksWhy This 1 Medical Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
BenzingaNovo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to meet on May 24 to review Novo Nordisk A/S’s (NYSE:NVO) application seeking approval for a once-weekly insulin icodec. In December 2023, the FDA said that data submitted by Novo Nordisk during the regulatory review is considered to constitute a major amendment to the Biologics License Application (BLA) for insulin icodec. Therefore, the regulatory review is extended by three months to provide time for a full submissio
